MRNS241220P4000
- 2.47
- 0.000.00%
Marinus Pharmaceuticals Newsroom
Marinus Pharmaceuticals Price Target Maintained With a $2.00/Share by HC Wainwright & Co.
Marinus Pharma Analyst Ratings
D. Boral Capital Maintains Buy on Marinus Pharma, Maintains $3 Price Target
JMP Securities Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
TD Cowen Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
RBC Capital Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating, Cuts Target Price to $1
TD Cowen Maintains Marinus Pharmaceuticals(MRNS.US) With Hold Rating
Marinus Pharma Analyst Ratings
Marinus Pharmaceuticals Price Target Cut to $1.00/Share From $3.00 by RBC Capital
Cantor Fitzgerald Maintains Overweight on Marinus Pharma, Lowers Price Target to $4
Oppenheimer Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating
A Quick Look at Today's Ratings for Marinus Pharmaceuticals(MRNS.US), With a Forecast Between $3 to $3
Marinus Downgraded After Setback to Late-stage Trial
Marinus (MRNS) Receives a Hold From RBC Capital
HC Wainwright Downgrades Marinus Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $2 From $11
Marinus Pharmaceuticals Cut to Market Perform From Market Outperform by JMP Securities
EF Hutton Maintains Buy on Marinus Pharma, Lowers Price Target to $3
Marinus Pharma Analyst Ratings
Marinus Pharma Analyst Ratings
EF Hutton Initiates Coverage On Marinus Pharma With Buy Rating, Announces Price Target of $23